Drug intelligence / Profile preview

ACTL

Development stage: Preclinical
Lead developer: Shandong Cancer Hospital
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

ACTL is a cell-based immunotherapy being investigated for its potential to prevent the recurrence and metastasis of stage III epithelial ovarian cancer. It involves the administration of a combination of dendritic cells (DC) and cytotoxic T lymphocytes (CTL).

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on ACTL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACTL.

Explore the full profile